Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 20Neoplasms 4Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Thoracic Neoplasms 1Solid Tumors 1Sarcoma 1Salivary Gland Neoplasms 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neuroendocrine Tumors 1Neoplasms, Unknown Primary 1Neoplasms by Site 1Multiple Endocrine Neoplasia Type 2a 1Melanoma 1Lymphoma, Large-Cell, Anaplastic 1Lung Neoplasms 1Lung Diseases 1Intestinal Neoplasms 1Intestinal Diseases 1Head and Neck Neoplasms 1Gastrointestinal Neoplasms 1Gastrointestinal Diseases 1Digestive System Neoplasms 1Digestive System Diseases 1Colorectal Neoplasms 1Colonic Diseases 1

Interventions

Gemcitabine 27Cisplatin 24pembrolizumab 15durvalumab 12Fluorouracil 11Capecitabine 10Oxaliplatin 9Leucovorin 8Bevacizumab 7Carboplatin 5Paclitaxel 4Nivolumab 4Irinotecan 4Injections 4zanidatamab 3trametinib 3lenvatinib 3derazantinib 3atezolizumab 3Ramucirumab 3Docetaxel 3tremelimumab 2surufatinib 2pertuzumab 2gemcitabine-oxaliplatin regimen 2envafolimab 2Trastuzumab 2S 1 (combination) 2Itraconazole 2Cetuximab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Biliary Tract Neoplasms × alectinib × Clear all
NCT02091141 2024-07-23

My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors

Genentech, Inc.

Phase 2 Completed
673 enrolled 22 charts
GastrointestinalGenitourinary

Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡